5-Year outcomes of the prospective and randomized cistcert study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients.
13 января 2021 года
18:29
5-Year outcomes of the prospective and randomized cistcert study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients.
Текст новости:
Title: 5-Year outcomes of the prospective and randomized cistcert study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients.
Author, co-author: Pipeleers, Lissa; Abramowicz, Daniel; Broeders, Nilufer; Lemoine, Alain; Peeters, Patrick; Van Laecke, Steven; WEEKERS, Laurent; Sennesael, Jacques; Wissing, Karl M.; Geers, Caroline; Bosmans, Jean-Louis
Abstract: BACKGROUND: Withdrawal of either steroids or calcineurin inhibitors are two strategies to reduce treatment-related side effects and improve long-term outcomes of kidney transplantation. The Cistcert study compared the efficacy and safety of these two strategies. METHODS: In this multi-center, randomized controlled trial, 151 incident kidney transplant recipients received cyclosporine (CsA), mycophenolic acid (MPA) and steroids during three months, followed by either steroid withdrawal (CsA/MPA) or replacement of cyclosporine with everolimus (EVL) (EVL/MPA/steroids). RESULTS: Five-year patient (89% vs 86%; p=NS) and death-censored graft survival (95% vs 96%; p=NS) were comparable in the CsA/MPA and EVL/MPA/steroids arm respectively. (51) CrEDTA clearance was comparable in the intention-to-treat analysis, but in the on-treatment population, the EVL/MPA/steroids arm exhibited a superior (51) CrEDTA clearance at 1 and 5 years after transplantation (61.6 vs 52.4, p=0.05 and 59.1 vs 46.2mL/min/1.73 m(2) , p=0.042). Numerically more and more severe rejections were observed in the EVL/MPA/steroids arm, which also experienced a higher incidence of post-transplant diabetes (26% versus 6%, p=0.0016) and infections. No significant differences were observed in cardiovascular outcomes and malignancy. CONCLUSIONS: Both regimens provide an excellent long-term patient and graft survival. Regarding graft function, EVL/MPA/steroids is an attractive strategy for patients with good tolerability who remain free of rejection.
Commentary: This article is protected by copyright. All rights reserved.
Связанные объекты: #All (найти в новостях).

Текст со страницы (автоматическое получение):
To cite this reference:
Title :
5-Year outcomes of the prospective and randomized cistcert study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients.
Language :
Abstract :
[en] BACKGROUND: Withdrawal of either steroids or calcineurin inhibitors are two strategies to reduce treatment-related side effects and improve long-term outcomes of kidney transplantation. The Cistcert study compared the efficacy and safety of these two strategies. METHODS: In this multi-center, randomized controlled trial, 151 incident kidney transplant recipients received cyclosporine (CsA), mycophenolic acid (MPA) and steroids during three months, followed by either steroid withdrawal (CsA/MPA) or replacement of cyclosporine with everolimus (EVL) (EVL/MPA/steroids). RESULTS: Five-year patient (89% vs 86%; p=NS) and death-censored graft survival (95% vs 96%; p=NS) were comparable in the CsA/MPA and EVL/MPA/steroids arm respectively. (51) CrEDTA clearance was comparable in the intention-to-treat analysis, but in the on-treatment population, the EVL/MPA/steroids arm exhibited a superior (51) CrEDTA clearance at 1 and 5 years after transplantation (61.6 vs 52.4, p=0.05 and 59.1 vs 46.2mL/min/1.73 m(2) , p=0.042). Numerically more and more severe rejections were observed in the EVL/MPA/steroids arm, which also experienced a higher incidence of post-transplant diabetes (26% versus 6%, p=0.0016) and infections. No significant differences were observed in cardiovascular outcomes and malignancy. CONCLUSIONS: Both regimens provide an excellent long-term patient and graft survival. Regarding graft function, EVL/MPA/steroids is an attractive strategy for patients with good tolerability who remain free of rejection.
Target :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
★★  13 января 2021 года
14:44
Les dernières contrindications à l'analgésie péridurale.
★★★  13 января 2021 года
14:18
Clinical evaluation of consciousness in the ICU
★★★  13 января 2021 года
14:15
Non-invasive brain stimulation in DOC – what’s new?
★★  13 января 2021 года
13:46
Neuromodulation, expériences et ouvertures
★★★  13 января 2021 года
13:44
FDG-Positron emission tomography: a measure of brain metabolism
ТОП-10 статей
1. Источник рассказал о планах по запуску новых спутников “Глонасс”
2. Нелинейные волновые и вихревые движения на поверхности жидкости
3. Формирование культуры чтения художественного текста у учащихся на начальном этапе литературного образования
4. Производитель двигателя для «грузовика» Ил-76 рассказал о его изменяемой конфигурации
5. "Prendre du recul par rapport à l'enseignement à distance"
6. Детские мечты о космосе сбываются
7. НАТО "прощупало" оборону российских войск во время учений в Черном море
8. Динамика фактора Виллебранда у больных с геморрагическим инсультом полушарной локализации в остром и отдаленном периодах
9. "Обеспечение работоспособности разнородного парка тракторов в системе технического сервиса АПК"
10. Морфогенез цервикальной неоплазии, ассоциированной с вирусами папилломы человека высокого канцерогенного риска


Ресурсы